Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.

BR, Ogutu; OJ, Apollo; D, McKinney; W, Okoth; J, Siangla; F, Dubovsky; K, Tucker; JN, Waitumbi; C, Diggs; J, Wittes; E, Malkin; A, Leach; A, Leach; LA, Soisson; JB, Milman; L, Otieno; CA, Holland; M, Polhemus; SA, Remich; CF, Ockenhouse; J, Cohen; WR, Ballou; SK, Martin; E, Angov; VA, Stewart; JA, Lyon; DG, Heppner; MR, Withers

doi:10.1371/journal.pone.0004708

Public

Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.

Shared by NobleBlocks on Mar 5, 2009 • 12:00 AM UTC

Authors:

Ogutu BR

Apollo OJ

McKinney D

Abstract

Objective The antigen, falciparum malaria protein 1 (FMP1), represents the 42-kDa C-terminal fragment of merozoite surface protein-1 (MSP-1) of the 3D7 clone of P. falciparum. Formulated with AS02 (a proprietary Adjuvant System), it constitutes the FMP1/AS02 candidate malaria vaccine. We evaluated t...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!